Claudio Marasca

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 142 publications

Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).

Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).

Journal: Dermatology and therapy

Published: July 14, 2026

Tildrakizumab in the Treatment of Complex and Severe Psoriasis: A Case Series.

Tildrakizumab in the Treatment of Complex and Severe Psoriasis: A Case Series.

Journal: Journal of clinical medicine

Published: June 17, 2026

Hidradenitis suppurativa: A paradigm of multidimensional burden and stigmatization.

Hidradenitis suppurativa: A paradigm of multidimensional burden and stigmatization.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 20, 2026

Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.

Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.

Journal: Clinical and experimental dermatology

Published: April 12, 2026

Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study.

Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study.

Journal: Journal of cutaneous medicine and surgery

Published: March 17, 2026

Living with hidradenitis suppurativa: The weight of fear, pain and endless uncertainty.

Living with hidradenitis suppurativa: The weight of fear, pain and endless uncertainty.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: December 09, 2025

Experiences and feedback from the JEADV Junior Editor Programme.

Experiences and feedback from the JEADV Junior Editor Programme.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: December 01, 2025

Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study.

Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study.

Journal: Clinical and experimental dermatology

Published: July 01, 2025

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.

Journal: International journal of dermatology

Published: May 21, 2025

Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.

Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.

Journal: Dermatology and therapy

Published: September 28, 2024

Reply to 'Burnout and professional quality of life in dermatologists'.

Reply to 'Burnout and professional quality of life in dermatologists'.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 19, 2024

Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.

Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.

Journal: Dermatology and therapy

Published: April 30, 2024

Showing 1-12 of 142

Last Updated: 09/26/2026